Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection.
D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000069446:Atazanavir Sulfate; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions / Q000502:physiology; D004351:Drug Resistance / Q000187:drug effects / Q000502:physiology; D000068679:Emtricitabine; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D007565:Jaundice / Q000139:chemically induced; D009842:Oligopeptides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D044966:Anti-Retroviral Agents; D009842:Oligopeptides; D011725:Pyridines; D003841:Deoxycytidine; D000069446:Atazanavir Sulfate; D000068679:Emtricitabine